Literature DB >> 24890957

Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010.

John D Turnidge1, Thomas Gottlieb2, David H Mitchell3, Geoffrey W Coombs4, Julie C Pearson4, Jan M Bell1.   

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2010 survey focussed on community-onset infections, examining isolates from urinary tract infections from patients presenting to outpatient clinics, emergency departments or to community practitioners. Two thousand and ninety-two Escherichia coli, 578 Klebsiella species and 268 Enterobacter species were tested using a commercial automated method (Vitek 2, BioMérieux) and results were analysed using Clinical and Laboratory Standards Institute breakpoints from January 2012. Of the key resistances, non-susceptibility to the third-generation cephalosporin, ceftriaxone, was found in 3.2% of E. coli and 3.2%-4.0% of Klebsiella spp. Non-susceptibility rates to ciprofloxacin were 5.4% for E. coli, 1.0%-2.3% for Klebsiella spp., and 2.5%-6.6% in Enterobacter spp, and resistance rates to piperacillin-tazobactam were 2.8%, 3.2%-6.9%, and 16.8%-18.0% for the same 3 groups respectively. Only 3 strains, 2 Klebsiella spp. and 1 Enterobacter spp, were shown to harbour a carbapenemase (IMP-4). This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au/cca.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24890957

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  7 in total

Review 1.  Carbapenem-resistant Enterobacteriaceae in the community: a scoping review.

Authors:  Ana M Kelly; Barun Mathema; Elaine L Larson
Journal:  Int J Antimicrob Agents       Date:  2017-06-21       Impact factor: 5.283

2.  Clinical and Microbiological Characteristics of Community-Onset Carbapenem-Resistant Enterobacteriaceae Isolates.

Authors:  Hangbin Hu; Jinchao Mao; Yiyi Chen; Jie Wang; Piaopiao Zhang; Yan Jiang; Qing Yang; Yunsong Yu; Tingting Qu
Journal:  Infect Drug Resist       Date:  2020-09-11       Impact factor: 4.003

Review 3.  Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Authors:  Bradley J Gardiner; Andrew J Stewardson; Iain J Abbott; Anton Y Peleg
Journal:  Aust Prescr       Date:  2019-02-01

Review 4.  Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.

Authors:  Ursula Theuretzbacher; Christine Årdal; Stephan Harbarth
Journal:  Infect Dis Rep       Date:  2017-03-30

5.  The Increased Length of Hospital Stay and Mortality Associated With Community-Associated Infections in Australia.

Authors:  Teresa M Wozniak; Amalie Dyda; Xing Lee
Journal:  Open Forum Infect Dis       Date:  2022-03-17       Impact factor: 4.423

6.  Overproduction of Chromosomal ampC β-Lactamase Gene Maintains Resistance to Cefazolin in Escherichia coli Isolates.

Authors:  Masato Kawamura; Ryota Ito; Yurina Tamura; Mio Takahashi; Miho Umenai; Yuriko Chiba; Takumi Sato; Shigeru Fujimura
Journal:  Microbiol Spectr       Date:  2022-06-06

Review 7.  Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Authors:  Kristin Ølfarnes Storhaug; Dag Harald Skutlaberg; Bent Are Hansen; Håkon Reikvam; Øystein Wendelbo
Journal:  Antibiotics (Basel)       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.